登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Engineering，3月20日，A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-20

  • A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System

    Author links open overlay panelYiminZhangaLiangYuaLingLingTangbMengfeiZhubYanqiJinaZhouhanWangaLanjuanLia

    Show more

    https://doi.org/10.1016/j.eng.2020.03.006

    Introduction

    The Corona Virus Disease 2019 (COVID-19) pan-epidemic, resulting from infection with the novel coronavirus 2019-nCoV (also known as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)), is currently the source of public health concern worldwide; however, treatment of this infection has been clinically challenging in many patients [1], [2]. Importantly, 2019-nCoV is the third fatal coronavirus that has emerged in the past two decades, following SARS and the Middle East respiratory syndrome (MERS) [2], [3]. The numbers of confirmed cases of COVID-19 infection and related deaths are still rising. As of 9 March 2020, there have been 80 754 confirmed cases and 3136 deaths in mainland China alone [4], corresponding to a total crude mortality of 3.88%.

  • 原文来源：https://www.sciencedirect.com/science/article/pii/S209580992030062X
21浏览量
原文链接
相关报告

  • 《3月20日_基于人工肝血液净化系统的COVID-19抗细胞因子风暴靶向治疗》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-20
    • 信息名称：基于人工肝血液净化系统的COVID-19抗细胞因子风暴靶向治疗 1.时间：2020年3月20日 2.机构或团队：浙江大学医学院第一附属医院、浙江树人大学树兰国际医学院附属树兰（杭州）医院 3.事件概要： 3月20日，Engineering期刊发表了来自浙江大学医学院第一附属医院、浙江树人大学树兰国际医学院附属树兰（杭州）医院的题为“A Promising Anti-Cytokine-Storm Targeted Therapy for COVID-19: The Artificial-Liver Blood-Purification System”的文章，阐述了基于人工肝血液净化系统的抗细胞因子风暴靶向治疗在SARS、MERS、H7N9以及COVID-19中的应用。 高细胞因子血症，也称为“细胞因子风暴”，是严重感染SARS、MERS、H5N1和H7N9的常见特征；它与疾病严重程度相关，是死亡率的预测因子。有研究均表明，SARS、MERS和H5N1流感等患者血清中促炎细胞因子/趋化因子水平都有所升高。先前的相关研究也显示，在COVID-19感染的重症和危重患者中，促炎细胞因子/趋化因子水平较高；此外，细胞因子风暴的存在与疾病的严重程度相关。 一些研究表明，通过由血液净化模块组成的人工肝血液净化系统可用于实现细胞因子/趋化因子清除。在SARS-CoV患者中，细胞因子风暴靶向疗法被推荐用于治疗继发于过度炎症反应的严重肺衰竭。采用该系统用于治疗H7N9感染患者也表现出很高的疗效。 鉴于细胞因子风暴靶向疗法在流感病毒感染的重症和危重患者中的疗效已得到证实，同样可能对治疗COVID-19感染的重症和危重患者有效。人工肝血液净化系统在浙江省已得到应用，对19例重症COVID-19患者进行了细胞因子风暴治疗，预后良好。基于上述证据，2月19日，李兰娟院士联合多名专家发布了《人工肝血液净化系统应用毒肺炎治疗的专家共识》。这项工作建议人工肝血液净化治疗COVID-19感染患者。 文章提出在未来进一步的研究中，并应考虑以下方面：首先，需要通过新型人工肝血液净化系统（即Li's人工肝系统（Li ALS））对COVID-19进行抗细胞因子风暴靶向治疗的多中心临床研究。其次，需要对COVID-19中细胞因子风暴发生的关键途径和免疫细胞类型进行研究，这将有助于理解人工肝支持系统治疗在减轻细胞因子风暴、重新平衡免疫系统来逆转严重COVID-19患者的过程。文章最后认为，作为一种抗细胞因子风暴靶向治疗，人工肝血液净化系统在降低COVID-19危重病人的死亡率方面具有很好的应用潜力。 4.附件： 原文链接 https://www.sciencedirect.com/science/article/pii/S209580992030062X
    36浏览量
    原文链接

  • 《LANCET，3月13日，COVID-19: consider cytokine storm syndromes and immunosuppression》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-03-14
    • COVID-19: consider cytokine storm syndromes and immunosuppression Published Online March 13, 2020 https://doi.org/10.1016/S0140-6736(20)30628-0 As of March 12, 2020, coronavirus disease 2019 (COVID-19) has been confirmed in 125 048 people worldwide, carrying a mortality of approximately 3·7%,1 compared with a mortality rate of less than 1% from influenza. There is an urgent need for effective treatment. Current focus has been on the development of novel therapeutics, including antivirals and vaccines. Accumulating evidence suggests that a subgroup of patients with severe COVID-19 might have a cytokine storm syndrome. We recommend identification and treatment of hyperinflammation using existing, approved therapies with proven safety profiles to address the immediate need to reduce the rising mortality.
    91浏览量
    原文链接